The advent of anti-nerve growth factor (NGF) monoclonal antibodies, such as bedinvetmab (LibrelaTM), has marked a significant advancement in the management of osteoarthritis (OA) pain in dogs (1, 2). Here, NGF is linked to osteoarthritis.